Research archive for ILMN

You may have noticed the Illumina share price drop below $300 a share on your weekly mini statement. The share price first hit $300 in July 2018 and peaked at $380 a share in July of this year. Why the recent fall?

On Thursday night Illumina reported their latest quarterly results. In August last year the share price was at $300 a share, and before the results it had managed to climb to $400 a share. Unfortunately, the numbers missed expectations and the stock dropped 11% to $355 a share.

What's going on with Vestact recommended stock Illumina? Bright did cover their first quarter numbers on the 6th of May, which were solid enough although the management team sounded anxious and withdrew earnings guidance for the rest of 2020. Since then the stock price is up a heart-warming 20%!

The genetics testing tools company Illumina, reported its Q1 numbers last week, showing an earnings surprise growth of 30.16%.The genetics company posted revenues of $859 million and earnings per share of $1.64 for the first quarter; beating analysts expectations for the fourth time in a row thanks to the stable demand for its gene sequencing machines.

Illumina is a company doing amazing things. Take a look at their latest product, the NextSeq 2000.

It's Jacaranda season in Joburg and earnings season in New York, as you can tell from our recent daily newsletters. Another of our main holdings in US portfolios is genetic sequencing machine maker Illumina, and they were also out with good third quarter results after the bell on Wall Street.

Here is a positive story to get your week off to a good start. Genetic test-kit company 23andMe (which uses lots of our company Illumina's sequencing machines) is using those test results to develop new drugs.

Gene sequencing giant Illumina reported its not so good second-quarter numbers. As we already new from a recent update, revenues fell short of management expectations as the company missed timelines for certain population genomic initiatives due to logistical issues. Leading to lower-than-expected direct-to-consumer sales.

Genetic sequencing machine maker Illumina has had a slow start as a Vestact recommended stock. It has fluctuated between $275 and $370 per share in recent months. The current price is $351.94.

On Thursday night one of our new additions to the Vestact portfolio, Illumina, reported their Q1 numbers. In case you have forgotten, Illumina is the leading company producing gene sequencing machines.

Gene sequencing giant Illumina reported Q4 numbers on Tuesday after the market close. The San Diego, California based company reported record revenues of $867 million, up 11% year-on-year. For the year 2018, Illumina reported $3.3 billion of revenues, up 21% thanks to strong demand for sequencing and array systems, consumables and services.

Our most recent recommended stock addition is Illumina, the San Diego-based company that makes genetic sequencing machines. These are used to map out a person's DNA from a blood or saliva sample. In the process, patients (including unborn children) can determine their heritage, and the likelihood of contracting certain health conditions. There are also ongoing research projects to develop personalised genetic therapies, using the sequencing information gathered by these complex instruments. Read our original stock buy note here.

Illumina is the latest addition to our recommended stocks in the US. In case you forgot what they are all about, here is a refresher. Illumina develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function.

What's the next big thing for humanity? Think about it. What is big today? Googling, Netflix, Discovery Vitality points, Amazon, Parkruns, iPhones and Instagram. Twenty years ago, it was Coca-Cola, blue jeans, bank notes, Camel cigarettes and the Lion King. But what's next? What will be big in 10 years' time? That's where we want to get invested!